These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 6820337)

  • 1. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
    Landgren BM; Johannisson E; Masironi B; Diczfalusy E
    Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
    Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
    Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
    Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
    Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
    Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
    Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
    Cekan SZ; Jia M; Landgren BM; Diczfalusy E
    Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
    Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
    Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.
    Alvarez F; Faundes A; Johansson E; Coutinho E
    Fertil Steril; 1983 Jul; 40(1):120-3. PubMed ID: 6407876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel.
    Xiao BL; Zhang XL; Feng DD
    Contraception; 1985 Nov; 32(5):455-71. PubMed ID: 3936678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
    Landgren BM; Diczfalusy E
    Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase.
    Shumin X; Johannisson E; Landgren BM; Diczfalusy E
    Contraception; 1983 Feb; 27(2):177-93. PubMed ID: 6851555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
    Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical staining of von Willebrand factor in endometrium of women during the first year of Norplant implants use.
    Au CL; Affandi B; Rogers PA
    Contraception; 1994 Nov; 50(5):477-89. PubMed ID: 7859456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic studies with a vaginal delivery system releasing levonorgestrel at a near zero order rate for one year.
    Landgren BM; Aedo AR; Cekan SZ; Diczfalusy E
    Contraception; 1986 May; 33(5):473-85. PubMed ID: 3093146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 micrograms/24 h when used alone or in combination with transdermal systems releasing estradiol.
    Landgren BM; Aedo AR; Johannisson E; Cekan SZ
    Contraception; 1994 Jul; 50(1):87-100. PubMed ID: 7924325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
    Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
    Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunolocalization of endothelin and neutral endopeptidase in the endometrium of users of subdermally implanted levonorgestrel (Norplant).
    Marsh MM; Butt AR; Riley SC; Rogers PA; Susil B; Affandi B; Findlay JK; Salamonsen LA
    Hum Reprod; 1995 Oct; 10(10):2584-9. PubMed ID: 8567775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days.
    Csemiczky G; Dieben T; Coeling Bennink HJ; Landgren BM
    Contraception; 1996 Dec; 54(6):333-8. PubMed ID: 8968661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
    Joshi UM; Joshi JV; Donde UM; Sankoli GM; Virkar KD; Saxena BN
    Contraception; 1985 Jan; 31(1):71-82. PubMed ID: 3921309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.